China Life Private Equity Investment

China Life Private Equity Investment Co., Ltd. is a specialized private equity investment institution operating under the umbrella of China Life, one of China's largest state-owned insurance and financial services groups. Established in June 2016, the firm serves as China Life's core platform for investments within the healthcare industry. It is dedicated to being a long-term value investor and partner, leveraging the comprehensive resources of its parent company to identify and support leaders in future industrial transformation.

The firm was founded in June 2016 and is registered in the Shanghai Free Trade Zone. Shortly after its establishment, in November 2016, China Life Private Equity launched the China Life Healthcare Fund, which quickly became a leading flagship private equity fund in China's healthcare sector. Notably, this fund was among the first insurance capital private equity funds to receive approval after the promulgation of relevant policies by the China Insurance Regulatory Commission.

China Life Private Equity focuses its investments across several key areas, including life science, med-tech, healthcare services, digital health, and broader technology investments. Its extensive portfolio includes notable companies such as Biocytogen, a leading one-stop service platform for new drug R&D; United Imaging Healthcare, an advanced medical imaging equipment company; XtalPi, a world-leading drug development technology company; and 4Paradigm, a prominent AI technology service provider. The firm has a track record of successful investments, with many portfolio companies achieving significant milestones, including IPOs.

The firm prides itself on a highly professional team with deep market insights and extensive investment experience. They foster an inclusive and collaborative environment that promotes excellence, aiming to capitalize on China Life's vast resources to drive innovation and value in their target sectors. China Life Private Equity actively seeks to invest in companies that are poised to lead future industrial changes, demonstrating a forward-looking investment philosophy.